MRModerna MRNA · NASDAQ
$200.10 -1.25% (-$2.53)
- Market cap
- $90.6B
- Enterprise value
- $90.1B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 40.7x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -40.0%
- Gross margin
- -12.6%
- Net margin
- -141.4%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.90
- Free float
- 93.2%
About the company
Moderna (MRNA) is a biopharmaceutical company specializing in the development of innovative drugs and vaccines. Their primary focus is on mRNA technology, which enables the creation of therapeutic and preventive products with high efficacy and safety. Moderna gained significant attention for its development of a COVID-19 vaccine, which has been approved and successfully deployed worldwide. Moderna stock is suitable for investors interested in the biotechnology sector and seeking opportunities in the field of therapeutic innovations and vaccines. Add Moderna stock to your watchlist on Bulios and be the first to receive updates on new developments, medical breakthroughs, and vaccines from this prominent company.
Sector
Healthcare
Industry
Biotechnology
CEO
Stéphane Bancel
Employees
4,700
Headquarters
Cambridge
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number